checkAd

     157  0 Kommentare Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference

    Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, June 10, 2021. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 9:40 a.m. ET.

    Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
    Long
    44,42€
    Basispreis
    0,48
    Ask
    × 8,66
    Hebel
    Short
    55,60€
    Basispreis
    0,63
    Ask
    × 6,58
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    About Bristol Myers Squibb

    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

    CorporateFinancial-News



    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, June 10, 2021. Chris Boerner, Ph.D., …

    Artikel zu den Werten

    Schreibe Deinen Kommentar

    Disclaimer